Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnnot_applicable

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

NCT06769555
not_yet_recruitingphase_1

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

NCT07407010
not_yet_recruitingphase_2

BCMA/CD3 BsAb Therapy for POEMS Syndrome

NCT07115654

Clinical Trials (3)

Showing 3 of 3 trials
NCT06769555Not Applicable

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Withdrawn
NCT07407010Phase 1

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Not Yet Recruiting
NCT07115654Phase 2

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3